{"id":"W2094417916","doi":"10.1007/s00280-010-1379-9","title":"Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of Calgary; McGill University; Dr. H. Bliss Murphy Cancer Centre; Saskatchewan Cancer Agency; Aptose Biosciences (Canada); Alberta Cancer Foundation","funders":"","keywords":"Medicine; Nimotuzumab; Chills; Rash; Toxicity; Internal medicine; Lung cancer; Regimen; Oncology; Gastroenterology; Radiation therapy; Phases of clinical research; Surgery; Cancer; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005722092,0.0004539246,0.0009625147,0.0001708785,0.0001912642,0.00003045611,0.0003223936,0.0003237559,0.002086994],"category_scores_gemma":[0.00000891935,0.0002666938,0.0002069844,0.0003893075,0.0006570937,0.0001014383,0.00001616948,0.0007328151,2.129812e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003126558,"about_ca_system_score_gemma":0.003589873,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.02209356,"about_ca_topic_score_gemma":0.03269015,"domain_scores_codex":[0.9973851,0.0001562224,0.0007411361,0.0006506059,0.0002794172,0.0007875506],"domain_scores_gemma":[0.998339,0.0003121838,0.0004618233,0.00028488,0.0001941537,0.0004079335],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4452667,0.004044638,0.2774375,0.0003356031,0.001070978,0.00004286729,0.00125724,0.00001776973,0.13941,0.00000358877,0.002184685,0.1289283],"study_design_scores_gemma":[0.7137001,0.0117514,0.05131566,0.0004455787,0.0003285118,0.00001827954,0.0000776342,0.002506786,0.115782,0.000002051365,0.1034044,0.0006677278],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870829,0.004047579,0.0002044659,0.001140482,0.001814315,0.0051257,0.0005294366,0.00001844699,0.00003667663],"genre_scores_gemma":[0.9742936,0.01774846,0.0002878909,0.005293462,0.0008977593,0.0009695238,0.00006145357,0.00009145035,0.0003564034],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2684333,"threshold_uncertainty_score":0.9999785,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03060500181438004,"score_gpt":0.4110274883242362,"score_spread":0.3804224865098562,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}